poisar

Stocks · News reference

UBS Maintains Buy on Colgate-Palmolive, Raises Price Target to $109

Benzinga Newsdesk

UBS analyst Peter Grom maintains Colgate-Palmolive (NYSE:CL) with a Buy and raises the price target from $106 to $109.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Leo Sun

    This Dividend King Was Removed From the S&P 100. Here's Why It's a Great Buy for Long-Term Investors Anyway.

    Colgate-Palmolive was removed from the S&P 100 index due to its $69 billion market cap being eclipsed by faster-growing AI-driven stocks, but the company remains a solid long-term investment. With 63 consecutive years of dividend increases, a 347% total return over 20 years, and expected 17% EPS CAGR through 2028, the stock offers stability and growth potential despite being a slower-growth consumer staples company.

    CLPANWANETSNDKSPGI
  2. Zacks.Com

    Will Pricing Sustain Procter & Gamble as Volume Growth Stays Elusive?

    Procter & Gamble faces a $1.4 billion after-tax earnings headwind in fiscal 2027 as it attempts to balance pricing strategies with volume growth in a challenging consumer environment. While pricing contributed to 1% organic sales growth in fiscal 2026, volume remained flat in Q4. PG plans to shift toward more balanced growth through innovation, promotions, and disciplined pricing rather than relying solely on price increases, which risk consumer trade-downs and reduced purchase frequency.

    PGCLCLX